A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
12/2004
12/30/2004	US20040266886 Cosmetic and/or pharmaceutical superfatting preparations
12/30/2004	US20040266884 Compounds for blocking androgen receptors
12/30/2004	US20040266873 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof
12/30/2004	US20040266870 Inhibitors of the chemotactic activation induced by the fraction C5a of complement and from other chemotactic proteins (chemokines) that y activate a 7-transmembrane-domain receptor; psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, fibrosis; antiischemic agents
12/30/2004	US20040266842 Thiazolyl substituted triazoles as alk5 inhibitors
12/30/2004	US20040266839 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors
12/30/2004	US20040266826 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
12/30/2004	US20040266823 Such as N-[1-(3-phenyl-3-benzoylamino]propyl)-4-piperidinyl]-N-ethylmethanesulfonylphenylacetamide; autoimmune and inflammatory diseases; rheumatoid arthritis; synthesis
12/30/2004	US20040266822 Secondary amines; tissue specificity; reduced side effects; cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasms, ischemia, anoxic nerve injury
12/30/2004	US20040266805 Inflammation modulatory compound
12/30/2004	US20040266793 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
12/30/2004	US20040266782 Cyclic amine derivatives-CCR-3 receptor antagonists
12/30/2004	US20040266780 Inhibitors of human phosphatidyl-inositol 3-kinase delta
12/30/2004	US20040266777 Pyridopyrazines and the use thereof as kinase inhibitors
12/30/2004	US20040266770 treating diseases that are triggered by persistent angiogenesis; inhibition of the VEGF receptor
12/30/2004	US20040266764 Hydroxamic acid derivatives
12/30/2004	US20040266750 Beta-lactamyl vasopressin v1aantagonists
12/30/2004	US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)
12/30/2004	US20040266725 Polysaccharide-containing compositions and use thereof
12/30/2004	US20040266720 Splice-region antisense composition and method
12/30/2004	US20040266699 Flavonoid compounds capable of modifying the dynamic and/or physical state of biological membranes and to stimulate the endogenous synthesis of stress proteins in eukaryotic cells, relative synthesis and their use
12/30/2004	US20040266694 Angiogenesis inhibitor induced by vascular endothelial growth factor
12/30/2004	US20040266686 Administering endothelial growth factor antagonist; wound healing agents
12/30/2004	US20040266679 Isolated ucleic acid; nucleotide sequence coding protein; detection moderators of kinase peptide
12/30/2004	US20040266678 Methods and compositions for treating polycystic ovary syndrome
12/30/2004	US20040266676 Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid
12/30/2004	US20040265971 Cytokine for use in stem cell propagation and treatment ot cardiovascular, bone, nervous system and inflammatory disorders
12/30/2004	US20040265968 Tissue plasminogen activator-like protease
12/30/2004	US20040265885 Peptide nucleic acid (PNA) derivatives which carry one or more phosphoryl radicals at the N terminus of the PNA backbone; can be purified using efficient methods such as chromatography or electrophoresis; use as pharmaceuticals and diagnostic agents
12/30/2004	US20040265396 comprises zinc oxide, calcium channel blocker (3,5-pyridinedicarboxylic acid or nifedipine), and fat-soluble vitamins (vitamins A, D, E, K) admixed with antibacterial and antifungal agents; administered orally or topically
12/30/2004	US20040265382 Methylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery
12/30/2004	US20040265252 trisubstituted triazines and agents that interact with prohibitin or mitochondrial ATPase to determine if the test compound inhibits or stimulates pigmentation; self-tanning; substituents are fluorophenoxy- and fluorobenzylamino- and a TRIETHYLENE GLYCOL DIAMINo-
12/30/2004	US20040261190 Hydrazono-malonitriles
12/29/2004	WO2004113331A1 Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
12/29/2004	WO2004113310A1 Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
12/29/2004	WO2004113300A1 Novel tricyclic heterocycle compound
12/29/2004	WO2004112837A1 PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR
12/29/2004	WO2004112815A1 Melanogenesis promoter and melanogenesis promoter composition
12/29/2004	WO2004112814A1 Nail restructuring compositions for topical application
12/29/2004	WO2004112808A2 Therapeutic use of lipids extracted from mother of pearl
12/29/2004	WO2004112805A1 Antimicrobial silver comprising silver
12/29/2004	WO2004112798A1 Compositions in the form of a spray comprising a pharmaceutical agent at least one volatile silicone and a non-volatile oily phase
12/29/2004	WO2004112785A1 New use iii
12/29/2004	WO2004112784A1 New use i
12/29/2004	WO2004112783A1 New use iv
12/29/2004	WO2004112782A1 New use v
12/29/2004	WO2004112781A1 New use ii
12/29/2004	WO2004112780A1 Metronidazole-based green tinted topical pharmaceutical composition
12/29/2004	WO2004112779A1 New use vii
12/29/2004	WO2004098578A3 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
12/29/2004	WO2004093832A3 Cosmetic or pharmaceutical composition comprising a combination of at least one diacylglycerol and at least one fatty alcohol
12/29/2004	WO2004064743A3 Modified retinoid compounds and their uses
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	WO2000061774A3 Bone morphogenic proteins
12/29/2004	EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions
12/29/2004	EP1491202A1 Nail restructuring compositions for topical application
12/29/2004	EP1491183A2 Use of a plant extract of the Rosaceae family
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490474A2 Method for producing pseudo islets
12/29/2004	EP1490406A1 Costimulatory molecule and its use
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490374A2 Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
12/29/2004	EP1490366A1 Novel alkoxypyridine-derivatives
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490354A1 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
12/29/2004	EP1490352A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
12/29/2004	EP1490343A1 New aryl imidazoles and related compounds as c5a receptor modulators
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490110A2 Anti-alpha v beta 6 antibodies
12/29/2004	EP1490107A1 Modulating angiogenesis
12/29/2004	EP1490092A1 Cosmetic or pharmaceutical composition containing peptides
12/29/2004	EP1490081A1 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
12/29/2004	EP1490077A1 A photoprotective orally administrable composition for skin
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
12/29/2004	EP1490065A1 Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
12/29/2004	EP1490064A1 Substituted pyridinones as modulators of p38 map kinase
12/29/2004	EP1490062A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490044A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
12/29/2004	EP1490020A1 Two-phase cosmetic or dermatological preparations
12/29/2004	EP1489915A1 Treatment and prevention of inflammatory disorders
12/29/2004	EP1402898B1 Antarticine-nf3 for the treatment and re-epithelialisation of wounds
12/29/2004	EP1267931B1 Rhodamine derivatives for photodynamic diagnosis and treatment
12/29/2004	EP1259114B1 A topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
12/29/2004	EP1248623B1 Treatment of diabetic ulcers
12/29/2004	EP1244657B1 Sulfonamides and derivatives thereof that modulate the activity of endothelin
12/29/2004	EP1242114A4 Use of enzymes for skin expansion
12/29/2004	EP1226136B1 Tyrosine kinase inhibitors
12/29/2004	EP1216234B1 Mediators of hedgehog signaling pathways, compositions and uses related thereto
12/29/2004	EP1214345B1 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
12/29/2004	EP1204646B1 1,4,5,6 -tetrahydropyrimidine derivative as a vitronectin inhibitor
12/29/2004	EP1196180B1 Treatment of angiogenesis dependent conditions with dextrin sulphate
12/29/2004	EP1135123B1 Use of isatin derivatives as ion channel activating agents
12/29/2004	EP1123274B1 Substituted phenyl derivatives, their preparation and use

1 ... 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 ... 1065